Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

The burden of depressive symptoms in people with schizophrenia.

Conley RR.

Psychiatr Clin North Am. 2009 Dec;32(4):853-61. doi: 10.1016/j.psc.2009.09.001.

PMID:
19944888
2.

Nonsomatic treatment of depression.

Sherrill JT, Kovacs M.

Child Adolesc Psychiatr Clin N Am. 2002 Jul;11(3):579-93. Review.

PMID:
12222084
3.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
5.

Management of schizophrenia with suicide risk.

Roy A, Pompili M.

Psychiatr Clin North Am. 2009 Dec;32(4):863-83. doi: 10.1016/j.psc.2009.08.005. Review.

PMID:
19944889
6.

The relationship between patient satisfaction and treatment outcomes in schizophrenia.

Chue P.

J Psychopharmacol. 2006 Nov;20(6 Suppl):38-56. Review.

PMID:
17046986
7.

Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review.

Sevy S, Visweswaraiah H, Mentschel C, Leucht S, Schooler NR.

J Clin Psychiatry. 2004 Jun;65(6):756-65. Review.

PMID:
15291652
8.

Antidepressants for the treatment of depression in people with schizophrenia: a systematic review.

Whitehead C, Moss S, Cardno A, Lewis G.

Psychol Med. 2003 May;33(4):589-99. Review.

PMID:
12785461
9.

Treatment-resistant schizophrenia--the role of clozapine.

Meltzer HY.

Curr Med Res Opin. 1997;14(1):1-20. Review.

PMID:
9524789
10.

Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.

Lambert M, Naber D.

CNS Drugs. 2004;18 Suppl 2:5-17; discussion 41-3. Review.

PMID:
15461312
11.

[Therapeutic alliance, a stake in schizophrenia].

Charpentier A, Goudemand M, Thomas P.

Encephale. 2009 Feb;35(1):80-9. doi: 10.1016/j.encep.2007.12.009. Epub 2008 May 19. Review. French.

PMID:
19250998
12.

Long-term treatment of mood disorders in schizophrenia.

Azorin JM.

Acta Psychiatr Scand Suppl. 1995;388:20-3. Review.

PMID:
7541599
13.

Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.

Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR, Major KA, Dow MG, Gumley AI.

Health Technol Assess. 2005 Nov;9(42):1-174. Review.

14.

Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia.

Vancampfort D, Knapen J, Probst M, van Winkel R, Deckx S, Maurissen K, Peuskens J, De Hert M.

Psychiatry Res. 2010 May 30;177(3):271-9. doi: 10.1016/j.psychres.2010.03.011. Epub 2010 Apr 20. Review.

PMID:
20406713
15.

Treatment resistance and other complicating factors in the management of schizophrenia.

Strassnig MT, Harvey PD.

CNS Spectr. 2014 Dec;19 Suppl 1:16-23; quiz 13-5, 24. doi: 10.1017/S1092852914000571. Epub 2014 Nov 20. Review.

PMID:
25410772
16.

Meeting everyday challenges: antipsychotic therapy in the real world.

Gorwood P.

Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S156-62. Epub 2006 Jul 25. Review.

PMID:
16872807
17.

[Incidence of the deficit form in refractory schizophrenia].

Samuelian JC.

Encephale. 1996 Jun;22 Spec No 2:19-23. Review. French.

PMID:
8767037
18.

The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.

Tamminga CA, Buchanan RW, Gold JM.

Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S21-6. Review.

PMID:
9690966
19.

Schizophrenia: management and family burden.

Sebit MB.

Cent Afr J Med. 2007 Sep-Dec;53(9-12):57-63. Review.

PMID:
20353127
20.

Elderly patients with schizophrenia and depression: diagnosis and treatment.

Felmet K, Zisook S, Kasckow JW.

Clin Schizophr Relat Psychoses. 2011 Jan;4(4):239-50. doi: 10.3371/CSRP.4.4.4. Review.

Supplemental Content

Support Center